The use of tools such as the Homeostatic Model Assessment (HOMA) index for evaluating insulin resistance [59], along with biomarkers such as adiponectin [60] and C-reactive protein [61], could allow for more precise stratification of metabolic risk in this population. The gene discussed is ADIPOQ; the disease is Insulin resistance.